Secukinumab: In psoriasis and beyond
Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Behç...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Journal of the Egyptian Women’s Dermatologic Society |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jewd.jewd_80_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850097404476391424 |
|---|---|
| author | Aditya K. Bubna Vinayak Viplav |
| author_facet | Aditya K. Bubna Vinayak Viplav |
| author_sort | Aditya K. Bubna |
| collection | DOAJ |
| description | Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Behçet’s disease. This review will throw light on secukinumab’s utility in psoriasis, as well as other dermatologic conditions. |
| format | Article |
| id | doaj-art-b4f46a6c56d7479eafd8d3238cca3321 |
| institution | DOAJ |
| issn | 2090-2565 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of the Egyptian Women’s Dermatologic Society |
| spelling | doaj-art-b4f46a6c56d7479eafd8d3238cca33212025-08-20T02:40:58ZengWolters Kluwer Medknow PublicationsJournal of the Egyptian Women’s Dermatologic Society2090-25652025-01-0122111210.4103/jewd.jewd_80_23Secukinumab: In psoriasis and beyondAditya K. BubnaVinayak ViplavSecukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Behçet’s disease. This review will throw light on secukinumab’s utility in psoriasis, as well as other dermatologic conditions.https://journals.lww.com/10.4103/jewd.jewd_80_23hidradenitis suppurativaoff-label dermatologic indicationspsoriasissecukinumab |
| spellingShingle | Aditya K. Bubna Vinayak Viplav Secukinumab: In psoriasis and beyond Journal of the Egyptian Women’s Dermatologic Society hidradenitis suppurativa off-label dermatologic indications psoriasis secukinumab |
| title | Secukinumab: In psoriasis and beyond |
| title_full | Secukinumab: In psoriasis and beyond |
| title_fullStr | Secukinumab: In psoriasis and beyond |
| title_full_unstemmed | Secukinumab: In psoriasis and beyond |
| title_short | Secukinumab: In psoriasis and beyond |
| title_sort | secukinumab in psoriasis and beyond |
| topic | hidradenitis suppurativa off-label dermatologic indications psoriasis secukinumab |
| url | https://journals.lww.com/10.4103/jewd.jewd_80_23 |
| work_keys_str_mv | AT adityakbubna secukinumabinpsoriasisandbeyond AT vinayakviplav secukinumabinpsoriasisandbeyond |